NFE2L2 and hepatocellular carcinoma: Given its role in antioxidant defense and drug resistance, Nrf2 could serve as a biomarker for predicting the aggressiveness of HCC or the likelihood of response to certain therapies, particularly those inducing oxidative stress in cancer cells.